News & Media
Press Center & More

Up-to-date press releases and statements in all categories, as well as materials for journalists.

May 13, 2022
Statement
COVID-19

Novavax Files for Emergency Use Authorization of COVID-19 Vaccine in Taiwan

May 9, 2022
Press release
Corporate and finance

Novavax Reports First Quarter 2022 Financial Results and Operational Highlights

May 6, 2022
Statement
COVID-19

Novavax Submits Variations to Expand Australian and New Zealand Provisional Approval of Nuvaxovid™ COVID-19 Vaccine to Adolescents aged 12 Through 17 Years

Media contact

Email: [email protected]
Phone: (240) 720-7804

Images, videos, and files for media use

Extensive materials for members of the press, including broadcast, online, film, radio and print journalists.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.